Hepatitis B and C are among the most common viral infections in the world. In 2017, at least 263 million people worldwide were carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.1,2
[WC2]Added in people to clarify “what or who” are the carriers
95% of people living with viral
hepatitis do not know it.
In 2016, the World Health Assembly adopted WHO’s first
“Global Health Sector Strategy on viral hepatitis,”
with the elimination of viral hepatitis as a public
health threat by 2030.
Globally, 263 million
persons are infected
72 countries projected to meet the 2030 target
of ≤0.1% HBsAg prevalence among 5-Year-Olds
Roche committed to the elimination of hepatitis
To advance global efforts and eliminate viral hepatitis, Roche is committed
to this motivational program underscoring our ongoing efforts to provide
life-saving diagnostics, and supports governments aiming to cure people
Roche is a leader in viral load testing and is dedicated to enabling
improved patient management by delivering innovative, high-quality
diagnostic solutions where they are needed most.
* In development
Additional Global Access Program Hepatitis Information